1. Home
  2. News & stories
  3. South Sudan: The world's first vaccination campaign to control an outbreak of hepatitis E

South Sudan: The world's first vaccination campaign to control an outbreak of hepatitis E

11 Oct 23

South Sudan: The world's first vaccination campaign to control an outbreak of hepatitis E

Debora Nyabol Gai is an MSF health promoter, helping to mobilise community members in Bentiu IDP camp to get vaccinated against hepatitis E. 
"People have an idea about hepatitis E because we did mobilisation activities before the vaccination. So when the vaccines were brought here, everyone show up for vaccination", said Debora. Caption
Debora Nyabol Gai is an MSF health promoter, helping to mobilise community members in Bentiu IDP camp to get vaccinated against hepatitis E. "People have an idea about hepatitis E because we did mobilisation activities before the vaccination. So when the vaccines were brought here, everyone show up for vaccination", said Debora.

21 July 2022

Juba, South Sudan - In a global first, health workers in South Sudan have carried out a vaccination campaign in response to an outbreak of hepatitis E, raising hopes in the fight against a disease that is especially fatal for pregnant women. Hepatitis E is the most common cause of acute viral hepatitis, causing approximately 20 million infections and 44,000 deaths per year. It is transmitted through faecal contamination of food and water. Large-scale outbreaks typically occur when water and sanitation are inadequate, such as in mass displacement camps. There is no specific treatment for hepatitis E, which as a fatality rate of up to 25 percent among pregnant women. It also increases the risk of spontaneous abortions and stillbirths.

Nyasunday is 19 years old and has lived in the IDP camp in Bentiu since 2014 when her and her family were fleeing conflict. For 3 weeks Nyasunday was experiencing severe pain when urinating, and then her eyes turned yellow and she had a high fever. She went to the MSF hospital to seek help and was diagnosed with hepatitis E. There is no treatment for hepatitis E - just supportive management of the symptoms and condition of the patients to try to reduce progression of the disease. Fortunately, after receiving care at MSF hospital, Nyasunday is now recovering.

"When I was taken to MSF my family thought that I was going to die. MSF found I was positive for hepatitis E and treated me as soon as possible. MSF is the reason why I am alive today", said Nyasunday. Caption
Nyasunday is 19 years old and has lived in the IDP camp in Bentiu since 2014 when her and her family were fleeing conflict. For 3 weeks Nyasunday was experiencing severe pain when urinating, and then her eyes turned yellow and she had a high fever. She went to the MSF hospital to seek help and was diagnosed with hepatitis E. There is no treatment for hepatitis E - just supportive management of the symptoms and condition of the patients to try to reduce progression of the disease. Fortunately, after receiving care at MSF hospital, Nyasunday is now recovering. "When I was taken to MSF my family thought that I was going to die. MSF found I was positive for hepatitis E and treated me as soon as possible. MSF is the reason why I am alive today", said Nyasunday.

"The fight against hepatitis E has been long and frustrating," said Dr Monica Rull, Medical Director, Médecins Sans Frontières (MSF). "Over the last two decades, MSF has been responding to hepatitis E outbreaks in displacement camps, trying to control the disease in challenging conditions and seeing the devastating impact on extremely vulnerable communities. With the experience of this vaccination campaign, we hope to change the way we tackle hepatitis E in the future."

"The fight against hepatitis E has been long and frustrating. Over the last two decades, MSF has been responding to hepatitis E outbreaks in displacement camps, trying to control the disease in challenging conditions and seeing the devastating impact on extremely vulnerable communities. With the experience of this vaccination campaign, we hope to change the way we tackle hepatitis E in the future."

DR MONICA RULL
|
MEDICAL DIRECTOR AT MSF

In March and April 2022, MSF and South Sudan's Ministry of Health jointly carried out the first two rounds of the hepatitis E vaccination campaign in Bentiu internally displaced persons camp in South Sudan's Unity state. Around 25,000 people, including pregnant women, have received the vaccine. A third and final round will be conducted in October 2022.

“Given the successful implementation and the community’s enthusiastic response in the first two rounds, this innovative vaccination campaign can serve as an example and be replicated in similar settings managing hepatitis E outbreaks," said Dr John Rumunu, Director General for Preventive Health Services, South Sudan Ministry of Health. "I hope the vaccine will help reduce infections and deaths from hepatitis E in Bentiu and beyond."

Nakia John is 16 years old and lives in Bentiu internally displaced persons camp. Nakia is being vaccinated against hepatitis E.
Starting in March 2022, MSF and South Sudan's Ministry of Health have jointly carried out a hepatitis E vaccination campaign in Bentiu in South Sudan's Unity State.  
This is the first time anywhere in the world that the only available hepatitis E vaccine (Hecolin) is being used in a mass vaccination campaign and in response to an active outbreak of hepatitis E. Caption
Nakia John is 16 years old and lives in Bentiu internally displaced persons camp. Nakia is being vaccinated against hepatitis E. Starting in March 2022, MSF and South Sudan's Ministry of Health have jointly carried out a hepatitis E vaccination campaign in Bentiu in South Sudan's Unity State. This is the first time anywhere in the world that the only available hepatitis E vaccine (Hecolin) is being used in a mass vaccination campaign and in response to an active outbreak of hepatitis E.

Bentiu is the largest displaced persons camp in South Sudan, created in 2014 at the height of the war. Today, approximately 112,000 people reside there, many having fled recent violence and flooding. MSF has been present in Bentiu since its inception and has seen hepatitis E outbreaks since 2015. The outbreaks are the consequence of appalling living conditions, including a lack of access to adequate water, sanitation and hygiene.

In 2021 extreme flooding and new influxes of displaced people exacerbated already deplorable living conditions, increasing the spread of waterborne illnesses, including hepatitis E. Since July 2021, in its Bentiu hospital MSF has seen 759 patients with confirmed hepatitis E, 17 of whom have died.

The Ministry of Health of South Sudan asked MSF to help its efforts to control the outbreak, through a large-scale vaccination campaign. The only available hepatitis E vaccine, Hecolin, has been shown in clinical trials to be highly effective at preventing disease, and the World Health Organization (WHO) has recommended that it be considered for use in outbreak responses since 2015. However, until now it has only been used on an individual basis in China, where it is licensed and used to vaccinate travellers. The vaccination campaign in Bentiu is the first time it has been used in response to a public health emergency.

Starting in March 2022, MSF and South Sudan's Ministry of Health have jointly carried out a hepatitis E vaccination campaign in Bentiu in South Sudan's Unity State.  This is the first time anywhere in the world that the only available hepatitis E vaccine (Hecolin©) is being used in a mass vaccination campaign and in response to an active outbreak of hepatitis E. Hecolin, has been shown in clinical trials to be highly effective at preventing disease, and the World Health Organization (WHO) has recommended that it be considered for use in outbreak responses since 2015. Caption
Starting in March 2022, MSF and South Sudan's Ministry of Health have jointly carried out a hepatitis E vaccination campaign in Bentiu in South Sudan's Unity State. This is the first time anywhere in the world that the only available hepatitis E vaccine (Hecolin©) is being used in a mass vaccination campaign and in response to an active outbreak of hepatitis E. Hecolin, has been shown in clinical trials to be highly effective at preventing disease, and the World Health Organization (WHO) has recommended that it be considered for use in outbreak responses since 2015.

A letter describing the vaccination campaign has been published today in The Lancet Infectious Diseases and a video presentation of the campaign can be found online here.

This is a significant milestone in global efforts to tackle hepatitis E," said Melanie Marti, Medical Officer, Immunization, Vaccines & Biologicals, WHO. "It is the first time a vaccine has been used to combat the effects of this potentially devastating disease. This is despite the fact that the vaccine has been licensed for over a decade, and it has been WHO policy to use it in outbreak settings since 2015. At the WHO we strongly encourage all countries experiencing an outbreak to use the vaccine against hepatitis E, including in pregnant women."

The success of the Bentiu vaccination campaign shows that it is possible to use the vaccine for outbreak response, even under difficult conditions. South Sudan’s Ministry of Health and MSF are monitoring and reporting on the results of the vaccination campaign. While other outbreak control measures are also necessary, including improving water and sanitation services, health officials believe this vaccination campaign is an important step toward reducing the burden of hepatitis E in the future. MSF hopes the campaign will encourage other countries to use the vaccine as part of measures to control outbreaks of hepatitis E.

Community health workers in Bentiu internally displaced persons camp, discussing the hepatitis E vaccination campaign. Caption
Community health workers in Bentiu internally displaced persons camp, discussing the hepatitis E vaccination campaign.